The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Ting Zou; Jun-Yan Liu; Li She; Ji-Ye Yin; Xi Li; Xiang-Ping Li; Hong-Hao Zhou; Juan Chen; Zhao-Qian Liu

doi:10.3389/fphar.2020.01029

The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Front Pharmacol. 2020 Jul 21:11:1029. doi: 10.3389/fphar.2020.01029. eCollection 2020.

Authors

Ting Zou^{1

2

3}, Jun-Yan Liu⁴, Li She^{5

6}, Ji-Ye Yin², Xi Li², Xiang-Ping Li⁷, Hong-Hao Zhou², Juan Chen⁷, Zhao-Qian Liu^{2

3}

Affiliations

¹ National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, China.
² Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, China.
³ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
⁴ Department of Orthopaedics, The First Affiliated Hospital of the University of South China, Hengyang, China.
⁵ Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
⁶ Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Xiangya Hospital, Central South University, Changsha, China.
⁷ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.

Abstract

Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related death in the world. Platinum-based chemotherapy plays an important role in lung cancer treatment, but the therapeutic effect varies from person to person. Heat shock proteins (HSPs) have been reported to be associated with the survival time of lung cancer patients, which may be a potential biomarker in lung cancer treatment. The aim of this study was to investigate the association between genetic polymorphisms and the prognosis in lung cancer patients treated with platinum-based chemotherapy.

Methods: We performed genotyping in 19 single nucleotide polymorphisms (SNPs) of HSP genes and Rho family genes of 346 lung cancer patients by SequenomMassARRAY. We used Cox proportional hazard models, state and plink to analyze the associations between SNPs and the prognosis of lung cancer patients.

Results: We found that the polymorphisms of HSPB1 rs2070804 and HSPA4 rs3088225 were significantly associated with lung cancer survival (p=0.015, p=0.049*, respectively). We also discovered the statistically significant differences between rs2070804 with age, gender, histology and stage, rs3088225 with gender and stage, which can affect lung cancer prognosis.

Conclusion: The results of our study suggest that HSPB1 rs2070804 (G>T) and HSPA4 rs3088225 (A>G) may be useful biomarkers for predicting the prognosis of lung cancer patients treated with platinum-based chemotherapy.

Keywords: genetic polymorphism; heat shock proteins; lung cancer; platinum-based chemotherapy; prognosis.